(NYSE: TEVA) Teva Pharmaceutical Industries's forecast annual revenue growth rate of 1.39% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Teva Pharmaceutical Industries's revenue in 2025 is $16,628,000,000.On average, 6 Wall Street analysts forecast TEVA's revenue for 2025 to be $19,391,870,429,713, with the lowest TEVA revenue forecast at $19,244,603,783,592, and the highest TEVA revenue forecast at $19,561,469,809,886. On average, 6 Wall Street analysts forecast TEVA's revenue for 2026 to be $19,456,534,179,753, with the lowest TEVA revenue forecast at $19,322,610,045,948, and the highest TEVA revenue forecast at $19,636,539,365,894.
In 2027, TEVA is forecast to generate $19,968,111,866,944 in revenue, with the lowest revenue forecast at $19,618,437,324,424 and the highest revenue forecast at $20,306,980,247,826.